Who are Banzel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludara, Xromi, Siklos, Rufinamid, Fludara, Fludarabin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rufinamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Banzel — Competitive Intelligence Brief

Banzel (RUFINAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: rufinamide. Area: Neuroscience.

marketed rufinamide Carbonic anhydrase 5A, mitochondrial Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Banzel (RUFINAMIDE) — Eisai. Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Banzel TARGET	RUFINAMIDE	Eisai	marketed	rufinamide	Carbonic anhydrase 5A, mitochondrial	2008-01-01
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	marketed	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01
Xromi	Xromi	Nova Laboratories Limited	marketed		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Siklos	Siklos	Theravia	marketed		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Rufinamid	Rufinamid	University of Zurich	marketed		Carbonic anhydrase 5A, mitochondrial, Sodium channel alpha subunit
Fludara	Fludara	Celyad Oncology SA	marketed		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit
Fludarabin	Fludarabin	Azienda Ospedaliera San Giovanni Battista	marketed		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (rufinamide class)

Eisai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Banzel — Competitive Intelligence Brief. https://druglandscape.com/ci/rufinamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab